Drug Profile
GW 250495
Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiasthmatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 07 Feb 2000 Discontinued-I for Asthma in United Kingdom (Inhalation)
- 24 Jun 1998 Phase-I clinical trials for Asthma in United Kingdom (Inhalation)
- 21 Apr 1998 New profile